RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. The stock is in a sharp event-driven selloff (FDA clinical holds tied to a neoplasm case) with elevated uncertainty and likely continued pressure. For an impatient buyer, the risk of further downside and headline volatility outweighs the potential rebound setup, even though it’s oversold and analysts remain broadly bullish long-term.
Trend is bearish and still weakening. MACD histogram is -0.441 and negatively expanding (downtrend momentum increasing). RSI(6) at 29.08 signals oversold/washed-out conditions, which can spark bounces, but oversold can persist during regulatory shocks. Moving averages are converging, implying a transition phase but not yet a confirmed reversal. Key levels: immediate support S1=10.473 (break risks a move toward S2=8.897). Resistance/pivot is 13.025, then R1=15.577. Pattern-based forecast also leans bearish near-term (higher probability of further declines next day/week).
Intellectia Proprietary Trading Signals:
Analyst community largely reiterates Buy/Overweight despite the hold (Clear Street $50, Stifel $45, Barclays $37, BofA $28; mostly sees limited thesis impact beyond delays). If FDA clarifies the neoplasm is non-causative and lifts/limits the hold, the stock could rebound sharply from oversold levels. Broader biotech backdrop cited as improving (M&A/financing tailwinds).
Primary overhang is the FDA clinical holds on RGX-111 and RGX-121 after a tumor/neoplasm case in a pediatric patient—this can drive prolonged uncertainty, potential program delay (including likely PDUFA delay), added safety monitoring, and valuation de-risking. Multiple news items reference investigations into potential securities fraud/omissions, adding legal/headline risk. Short-term technicals and options flow point to continued bearish pressure.
Latest reported quarter: 2025/Q3. Revenue rose to $29.733M (+22.88% YoY), indicating improving topline (likely collaboration/royalty-driven). Losses improved modestly: net income was -$61.941M (3.93% YoY improvement) and EPS -1.20 (2.56% YoY improvement). Gross margin increased to 80.75 (reported +65.44% YoY), showing strong margin profile on recognized revenue, but the company remains meaningfully loss-making—so regulatory setbacks can materially affect funding/risk perception.
Recent trend is broadly supportive with rising/strong targets into late 2025/early 2026 (BofA PT to $28; Stifel to $45; Barclays initiated Overweight $37). After the FDA hold, Clear Street and Stifel reiterated Buy ratings with high price targets, arguing the market reaction may be excessive and that some programs may be insulated (per Stifel, RGX-202 and RGX-314 should NOT be impacted; RGX-121 likely delayed). Wall Street pros: large upside to targets and belief the hold may be containable. Cons: near-term thesis is dominated by FDA/regulatory risk and timing uncertainty, which can overwhelm fundamentals and targets.
